A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progression
Plebanek, M. P.; Xue, Y.; Nguyen, Y.-V.; DeVito, N.; Wang, X.; Holtzhausen, A.; Beasley, G.; Yarla, N.; Theivanthiran, B.; Hanks, B. A.
Show abstract
Dendritic cells (cDCs) are essential mediators of anti-tumor immunity. Cancers have developed mechanisms to render DCs dysfunctional within the tumor microenvironment. Utilizing CD63 as a unique surface marker, we demonstrate that mature regulatory DCs (mregDCs) suppress DC antigen cross-presentation while driving TH2 and regulatory T cell differentiation within tumor-draining lymph node tissues. Transcriptional and metabolic studies show that mregDC functionality is dependent upon the mevalonate biosynthetic pathway and the master transcription factor, SREBP2. Melanoma-derived lactate activates DC SREBP2 in the tumor microenvironment (TME) and drives mregDC development from conventional DCs. DC-specific genetic silencing and pharmacologic inhibition of SREBP2 promotes anti-tumor CD8+ T cell activation and suppresses melanoma progression. CD63+ mregDCs reside within the sentinel lymph nodes of melanoma patients. Collectively, this work describes a tumor-driven SREBP2-dependent program that promotes CD63+ mregDC development and function while serving as a promising therapeutic target for overcoming immune tolerance in the TME. One Sentence SummaryThe metabolic transcription factor, SREBF2, regulates the development and tolerogenic function of the mregDC population within the tumor microenvironment.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- IL-3-driven T cell-basophil crosstalk enhances anti-tumor immunity 97%
- The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive anti-tumor immunity in the brain 96%
- Targeting macrophages with CAR-T cells delays solid tumor progression and enhances anti-tumor immunity 95%
Similar papers in this journal
Similar papers in this journal
- A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response 96%
- Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response 95%
- Single-Cell Multiomics Defines Tolerogenic Extrathymic Aire-Expressing Populations with Unique Homology to Thymic Epithelium 95%
Similar papers in this journal
- An autophagy program that promotes T cell egress from the lymph node controls responses to immune checkpoint blockade 97%
- Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
Similar papers in this journal
- Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion 96%
- B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma 96%
- The spontaneous neoantigen-specific CD4+ T cell response to a growing tumor is functionally and phenotypically diverse. 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.